



VERIFICATION OF TRANSLATION

I, Tadaaki Nomura
of c/o Techlex Co., Ltd. located at 7-6, Koishikawa 1-chome,
Bunkyo-ku, Tokyo 112-0002 Japan
declare as follows:

1. That I am well acquainted with both the English and Japanese languages, and
2. That the attached document is a true and correct translation made by me to the best of my knowledge and belief, of Japanese Patent Application No. 47571/99.

April 22, 2004
(Date)

Tadaaki Nomura
(Signature of Translator)



[Name of Document]
Application for Patent
[Reference Number]
H10-2031N2
5 [Filing Date]
February 25, 1999
[Addressee]
Commissioner, Patent Office
[International Identification]
10 C12N 15/54
[Inventor]
[Address] 5-1082-1, Mukohara, Higashiyamato-shi, Tokyo,
Japan
[Name] Hisashi Narimatsu
15 [Inventor]
[Address] 2-32, Futamatagawa, Asahi-ku, Yokohama-shi,
Kanagawa, Japan
[Name] Soichiro Issiki
[Inventor]
20 [Address] 1-11-42, Shimosato, Higashikurume-shi, Tokyo,
Japan
[Name] Akira Togayachi
[Inventor]
[Address] c/o Tokyo Research Laboratories, KYOWA HAKKO
25 KOGYO CO., LTD.,
6-6, Asahi-machi 3-chome, Machida-shi, Tokyo,
Japan
[Name] Katsutoshi Sasaki
[Applicant]
30 [Identification Number] 000001029
[Name] Kyowa Hakko Kogyo Co., Ltd.
[Representative] Tadashi Hirata
[Indication of Fees]
[Prepayment Book Number] 008187
35 [Amount of Payment] 21000 yen
[List of Submitted Articles]

[Name of Article]	Specification	1 copy
[Name of Article]	Abstract	1 copy
[Name of Article]	Drawings	1 copy
[Necessity of Proofing]	Yes	

[Name of Document] SPECIFICATION

[Title of the Invention] NOVEL POLYPEPTIDES

5 [Scope of Claim for Patent]

[Claim 1] A polypeptide having β 1,3-galactosyltransferase activity involved in the synthesis of sialyl-Lewis a sugar chain, present in colon cancer cells expressing sialyl-Lewis a sugar chain.

10 [Claim 2] A polypeptide selected from the following (a), (b) and (c):

(a) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 1,

15 (b) a polypeptide containing the amino acid sequence of 31 to 310 in the amino acid sequence represented by SEQ ID NO: 1, and

(c) a polypeptide consisting of an amino acid sequence where in the amino acid sequence of the polypeptide (a) or (b), one to several amino acids have
20 been deleted, replaced or added and having β 1,3-galactosyltransferase activity capable of synthesizing Gal β 1-3GlcNAc structure.

[Claim 3] A polypeptide according to claim 1 or 2 wherein the β 1,3-galactosyltransferase activity is the activity of
25 transferring galactose via β 1,3-linkage to N-acetylglucosamine residue present at the non-reducing terminus of a sugar chain.

[Claim 4] A polypeptide according to claim 1 or 2 wherein the β 1,3-galactosyltransferase activity is the activity of
30 transferring galactose via β 1,3-linkage to N-acetylglucosamine residue present at the non-reducing terminus of GlcNAc β 1-3Gal β 1-4Glc or to N-acetylglucosamine monosaccharide.

[Claim 5] A DNA selected from the following (a), (b), (c)
35 and (d):

(a) DNA coding for the polypeptide described in any